Search results for "antipsychotic"

showing 10 items of 189 documents

Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year r…

2009

BackgroundEmpirical evidence of the efficacy and effectiveness of psychosocial family intervention and of the specificity of its effects on the course of schizophrenia is limited. The aim was to study the efficacy and effectiveness of psychosocial family intervention with regard to clinical and social functioning and family burden after controlling for compliance and several prognostic factors.MethodA 2-year randomized controlled trial with blind assessments. Fifty patients with DSM-IV schizophrenia and persistent positive symptoms and/or previous clinical relapse were allocated to psychosocial family intervention, individual counselling and standard treatment versus individual counselling …

AdultMaleFamily therapymedicine.medical_specialtylaw.inventionYoung AdultCost of IllnessRandomized controlled triallawIntervention (counseling)Secondary PreventionmedicineHumansSchizophreniform disorderPsychiatryApplied PsychologyPsychiatric Status Rating ScalesStandard treatmentSocial environmentmedicine.diseaseCombined Modality TherapyPsychotherapyPsychiatry and Mental healthTreatment OutcomeCaregiversPsychotic DisordersSpainSchizophreniaSchizophreniaPatient ComplianceFamily TherapyFemaleSchizophrenic PsychologyPsychologySocial AdjustmentPsychosocialAntipsychotic AgentsPsychological Medicine
researchProduct

Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study

2016

Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain. Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([125I]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left p…

AdultMaleGene ExpressionVasotocinReal-Time Polymerase Chain ReactionLeft nucleusRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHaloperidolAnimalsHumansRNA MessengerClozapineBiological PsychiatryClozapineAgedAged 80 and overTemporal cortexBinding SitesBrainMiddle Agedmedicine.diseaseOxytocin receptor030227 psychiatryPsychiatry and Mental healthchemistryOxytocinReceptors OxytocinSchizophreniaSchizophreniaAutoradiographyHaloperidolFemalePsychologyNeurosciencehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugSchizophrenia Research
researchProduct

Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers

2002

The increased rate of smoking in schizophrenia patients remains unexplained and may reflect attempts at self-treatment. The effect sought from smoking may be related to nicotine's stimulating action. We tested this hypothesis by examining the relationship between smoking status and finger tapping rate, a measure of central processing, in schizophrenia patients treated with atypical antipsychotics. Smokers showed significantly faster finger tapping rates than non-smokers. This was not related to clinical state, illness chronicity, medication side-effects, antipsychotic dose or plasma concentrations. Nicotine can improve central processing in medicated schizophrenia patients and this may cons…

AdultMaleNicotinemedicine.medical_specialtyPatientsMovementmedicine.medical_treatmentClinical stateFingersNicotineInternal medicinemedicineHumansPharmacology (medical)Nicotinic AgonistsAntipsychoticPsychiatryBiological PsychiatryPharmacologySmokeAnalysis of VarianceSmokingMiddle Agedmedicine.diseasePsychiatry and Mental healthNeurologySchizophreniaFinger tappingPlasma concentrationSchizophreniaSmoking statusNeurology (clinical)PsychologyPsychomotor Performancemedicine.drugEuropean Neuropsychopharmacology
researchProduct

High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.

2003

The 'atypicality' of the antipsychotic drug, amisulpride, has been attributed to preferential extrastriatal binding. Previous investigations of striatal D2 receptor occupancy by amisulpride revealed conflicting results. The aim of this PET study was to measure the striatal occupancy by amisulpride and to correlate it with the corresponding drug plasma concentrations. Nine amisulpride-treated patients and 12 healthy volunteers serving as controls were studied with PET and [18F]desmethoxyfallypride. Occupancy values and plasma concentrations were nonlinearly fitted to an E max model. Results showed 43-85% (putamen) and 67-90% (caudate) D2-like receptor occupancy. Plasma amisulpride concentrat…

AdultMaleOccupancyPharmacologyDopamine receptor D2Image Interpretation Computer-AssistedSalicylamidesmedicineHumansPharmacology (medical)AmisulprideReceptorPharmacologyCerebral CortexChemistryReceptors Dopamine D2PutamenDesmethoxyfallypridePutamenMiddle Agedmedicine.diseaseNeostriatumPsychiatry and Mental healthSchizophreniaDopamine receptorArea Under CurvePositron-Emission TomographySchizophreniaFemaleAmisulprideCaudate NucleusRadiopharmaceuticalsSulpirideAlgorithmsmedicine.drugAntipsychotic AgentsThe international journal of neuropsychopharmacology
researchProduct

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

2004

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treat…

AdultMaleOlanzapineAdolescentPolysomnographymedicine.medical_treatmentPolysomnographySeverity of Illness IndexDrug Administration ScheduleBenzodiazepinesSurveys and QuestionnairesmedicineHumansPharmacology (medical)AntipsychoticSleep disorderSleep Stagesmedicine.diagnostic_testElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animalsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthDelta RhythmOlanzapineSchizophreniaAnesthesiaDelta RhythmSchizophreniaSchizophrenic PsychologySleep StagesPsychologyAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study

2009

AbstractObjectiveTo examine the predictive validity of early improvement in a naturalistic sample of inpatients and to identify the criterion that best defines early improvement.MethodsTwo hundred and forty-seven inpatients who fulfilled ICD-10 criteria for schizophrenia were assessed with the Positive And Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the recently proposed consensus criteria, response as a reduction of at least 40% in the PANNS total score from admission to discharge.ResultsReceiver operating characteristic (ROC) analyses showed that early improvement (reduction of the PANSS total sco…

AdultMalePredictive validitymedicine.medical_specialtyDrug trialAdolescentmedicine.medical_treatmentConsensus criteriaSensitivity and SpecificitySeverity of Illness Index03 medical and health sciences0302 clinical medicineNaturalistic observationInternational Classification of DiseasesInternal medicinemedicineHumans030212 general & internal medicinePsychiatryAntipsychoticAgedPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleReceiver operating characteristicPatient SelectionMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTranquilizing AgentsTreatment OutcomeROC CurveSchizophreniaArea Under CurveSchizophreniaFemalePsychologyAntipsychotic AgentsFollow-Up StudiesEuropean Psychiatry
researchProduct

Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patien…

1991

The new tetracyclic compound savoxepine exhibits potent antidopaminergic effects with preferential activity in the hippocampus as compared to striatum in rat brain. As a result of behavioural animal models and regional differences in dopamine receptor binding characteristics, it has been suggested to possess an "atypical" neuroleptic response pattern. In an open clinical trial, savoxepine was administered to 12 in-patients suffering from paranoid schizophrenia and schizophreniform disorder (DSM-III). Eight patients were treated with a stable dose of 0.5 mg per day throughout the study, while in the remaining patients higher doses up to 20 mg/day were administered. Mean total BPRS scores and…

AdultMalePsychosisParanoid schizophreniamedicine.medical_treatmentPharmacologyExtrapyramidal symptomsBasal Ganglia DiseasesmedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesDopamine antagonistDopamine receptor bindingMiddle Agedmedicine.diseaseEnzymesDisease Models AnimalSchizophreniaDibenzoxazepinesSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologymedicine.drugAntipsychotic AgentsPsychopharmacology
researchProduct

Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

2000

SummaryIn this multicentre study the two-year outcome of two groups of consecutive patients (total N = 106) with first-episode functional non-affective psychosis, both treated according to the ‘need-specific Finnish model’, which stresses teamwork, patient and family participation and basic psychotherapeutic attitudes, was compared. No alternative treatment facilities were available in the study sites. The two study groups differed in the use of neuroleptics: three of the sites (the experimental group) used a minimal neuroleptic regime whilst the other three (the control group) used neuroleptics according to the usual practice. Total time spent in hospital, occurrence of psychotic symptoms …

AdultMalePsychosismedicine.medical_specialtyAdolescentChlorpromazine050109 social psychologyOutcome (game theory)Catchment Area HealthmedicineHumansPsychiatric hospital0501 psychology and cognitive sciencesPsychiatryFinlandPatient Care Teambusiness.industryPublic health05 social sciences050301 educationSocial environmentMiddle Agedmedicine.diseaseMental healthClinical trialPsychiatry and Mental healthTreatment OutcomePsychotic DisordersPhysical therapyFemalebusinessAttitude to Health0503 educationPsychosocialAntipsychotic AgentsEuropean Psychiatry
researchProduct